Evidence that exposure to progesterone alone is a sufficient stimulus to cause a precipitous rise in the immunomodulatory protein the progesterone induced blocking factor (PIBF)
参考文献:1.Lachmann M, Gelbmann D, Kalman E, Polgar B, Buschle M, von Gabain A, et al. PIBF (progesterone induced blocking factor) is overexpressed in highly proliferating cells and associated with the centrosome. Int J Cancer. 2004;112:51–60.CrossRef PubMed 2.Polgar B, Kispal GY, Lachmann M, Paar C, Nagy E, Csere P, et al. Molecular cloning and immunological characterization of a novel cDNA coding for PIBF. J Immunol. 2003;171:5956–63.CrossRef PubMed 3.Szekeres-Bartho J, Hadnagy J, Pacsa AS. The suppressive effect of progesterone on lymphocyte cytotoxicity: unique progesterone sensitivity of pregnancy lymphocytes. J Reprod Immunol. 1985;7:121–8.CrossRef PubMed 4.Szekeres-Bartho J, Autran B, Debre P, Andreu G, Denver L, Chaouat G. Immunoregulatory effects of a suppressor factor from healthy pregnant women’s lymphocytes after progesterone induction. Cell Immunol. 1989;122:281–94.CrossRef PubMed 5.Szekeres-Bartho J, Szekeres GY, Debre P, Autran B, Chaouat G. Reactivity of lymphocytes to a progesterone receptor-specific monoclonal antibody. Cell Immunol. 1990;125:273–83.CrossRef PubMed 6.Polgar B, Barakony A, Xinos I, Szekeres-Bartho J. The role of γ/δ TCR positive cells in pregnancy. Am J Reprod Immunol. 1999;41:239–44.CrossRef PubMed 7.Szekeres-Bartho J, Barakonyi A, Polgar B, Par G, Faust Z, Palkovics T, et al. The role of γ/δ T cells in progesterone-mediated immunomodulation during pregnancy: a review. Am J Reprod Immunol. 1999;42:44–8.CrossRef PubMed 8.Hansen KA, Opsahl MS, Nieman LK, Baker Jr JR, Klein TA. Natural killer cell activity from the pregnant subjects is modulated by RU 486. Am J Obstet Gynecol. 1992;166:87–90.CrossRef PubMed 9.Szekeres-Bartho J, Kilar F, Falkay G, Csernus V, Torok A, Pacsa AS. Progesterone-treated lymphocytes of healthy pregnant women release a factor inhibiting cytotoxicity and prostaglandin synthesis. Am J Reprod Immunol Microbiol. 1985;9:15–8.CrossRef PubMed 10.Ivanova-Todorova E, Kyurkchiev DS, Nalbanski A, Timeva T, Shterev A, Kyurkchiev SD. Production and characterization of a novel monoclonal antibody against progesterone-induced blocking factor (PIBF). J Reprod Immunol. 2008;78:94–101.CrossRef PubMed 11.Szekeres-Bartho J, Weill BJ, Mike G, Houssin D, Chaouat G. Progesterone receptors in lymphocytes of liver-transplanted and transfused patients. Immunol Lett. 1989;22:259–61.CrossRef PubMed 12.Chiu L, Nishimura M, Ishi Y, Nieda M, Maeshima M, Takedani Y, et al. Enhancement of the expression of progesterone receptor on progesterone-treated lymphocytes after immunotherapy in unexplained recurrent spontaneous abortion. Am J Reprod Immunol. 1996;35:552–7.CrossRef PubMed 13.Check JH, Arwitz M, Gross J, Peymer M, Szekeres-Bartho J. Lymphocyte immunotherapy (LI) increases serum levels of progesterone induced blocking factor. Am J Reprod Immunol. 1997;37:17–20.CrossRef PubMed 14.Check JH, Szekeres-Bartho J, O’Shaughnessy A. Progesterone induced blocking factor seen in pregnancy lymphocytes soon after implantation. Am J Reprod Immunol. 1996;35:277–80.CrossRef PubMed 15.Check JH, Arwitz M, Gross J, Szekeres-Bartho J, Wu CH. Evidence that the expression of progesterone-induced blocking factor by maternal T-lymphocytes is positively correlated with conception. Am J Reprod Immunol. 1997;38:6–8.CrossRef PubMed 16.Check JH, Nazari P, Check ML, Szekeres-Bartho J, Yuan W. Evidence that the adverse effect of controlled ovarian hyperstimulation on successful pregnancy outcome following embryo transfer may be related to premature trophoblast invasion. Clin Exp Obstet Gynecol. 2002;29:83–6.PubMed 17.Check JH, Check ML. Evidence that failure to conceive despite apparent correction of ovulatory defects by follicle-maturing drugs may be related to premature trophoblast invasion. Med Hypotheses. 2002;59:385–8.CrossRef PubMed 18.Chien EJ, Liao CF, Chang CP, Pu HF, Lu LM, Shie MC, et al. The non-genomic effects on NA(+)/H(+)-exchange 1 by progesterone and 20 alpha-hydroxyprogesterone in human T cells. J Cell Physiol. 2007;211:544–50.CrossRef PubMed 19.Lai JN, Wang OY, Lin VH, Liao CF, Tarng DC, Chien EJ. The non-genomic rapid acidification in peripheral T cells by progesterone depends on intracellular calcium increase and not an Na+/H + -exchange inhibition. Steroids. 2012;77:1017–24.CrossRef PubMed 20.Falkenstein E, Norman AW, Wehling M. Mannheim classification of nongenomically initiated (rapid) steroid action(s). J Clin Endocrinol Metab. 2000;85:2072–5.CrossRef PubMed 21.Ober C, Steck T, van der Ven K, Billstrand C, Messer L, Kwak J, et al. MHC class II compatibility in aborted fetuses and term infants of couples with recurrent spontaneous abortion. J Reprod Immunol. 1993;25:195–207.CrossRef PubMed 22.Dizon-Townson D, Nelson L, Scott JR, Ware Branch D, Ward K. Human leukocyte antigen DQ alpha sharing is not increased in couples with recurrent miscarriage. Am J Reprod Immunol. 1995;34:209–12.CrossRef PubMed 23.Wagenknecht DR, Green KM, McIntyre JA. Analyses of HLA-DQ alleles in recurrent spontaneous abortion (RSA) couples. Am J Reprod Immunol. 1997;37:1–6.CrossRef PubMed 24.Check JH, Choe JK, Ubelacker L, DiAntonio A. Maternal/paternal sharing of DQ-alpha type II histocompatibility antigens not associated with pregnancy outcome following in vitro fertilization (IVF)-embryo transfer (ET). Clin Exp Obstet Gynecol. 2001;28:142–3.PubMed 25.Srivastava MD, Thomas A, Srivastava BI, Check JH. Expression and modulation of progesterone induced blocking factor (PIBF) and innate immune factors in human leukemia cell lines by progesterone and mifepristone. Leuk Lymphoma. 2007;48:1610–7.CrossRef PubMed 26.Check JH, Cohen R. The role of progesterone and the progesterone receptor in human reproduction and cancer. Expert Rev Endocrinol Metab. 2013;8:469–4.CrossRef 27.DiAntonio G, Check JH, DiAntonio A, Duroseau M. The progesterone (P) receptor antagonist mifepristone does not lower serum progesterone induced blocking factor (PIBF) in the presence of P. 63rd Annual Meeting of the Pacific Coast Reproductive Society, Rancho Mirage, California, March 11–15, 2015. Fertil Steril. 2015;103(2):e18.CrossRef 28.Usadi RS, Groll JM, Lessey BA, Lininger RA, Zaino RJ, Fritz MA, et al. Endometrial development and function in experimentally induced luteal phase deficiency. J Clin Endocrinol Metab. 2008;93:4058–64.PubMedCentral CrossRef PubMed 29.The Practice Committee of the American Society for Reproductive Medicine. The clinical relevance of luteal phase deficiency: a committee opinion. Fertil Steril. 2012;98:1112–7.CrossRef
作者单位:Rachael A. Cohen (1) Jerome H. Check (2) (4) Michael P. Dougherty (3)
1. Department of Obstetrics and Gynecology, Philadelphia College of Osteopathic Medicine, Philadelphia, PA, USA 2. Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Cooper Medical School of Rowan University, Camden, NJ, USA 4. 7447 Old York Road, Melrose Park, PA, 19027, USA 3. Department of Obstetrics, Gynecology and Reproductive Sciences, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA
刊物类别:Medicine
刊物主题:Medicine & Public Health Gynecology Developmental Biology Human Genetics
出版者:Springer Netherlands
ISSN:1573-7330
文摘
Purpose To determine if exposure to progesterone alone is sufficient to increase the production of the immunomodulatory protein known as the progesterone induced blocking factor (PIBF). Also to determine what method of progesterone delivery or form of P best stimulates PIBF secretion.